Use of high concentration contrast media (HCCM): principles and rationale—body CT

Abstract

Numerous complex pharmacokinetic interrelationships affect the use of contrast media for computed tomography (CT) imaging. The volume, concentration, and rate of injection, all affect the degree of enhancement that is achieved with an injection of contrast material. In addition, the injection technique, whether the contrast is infused with a constant injection rate (uniphasic injection) or whether the rate is altered during the injection (multiphasic injection) also affect the magnitude and duration of contrast enhancement. In body CT imaging, the liver poses unique challenges in managing the use of intravenous contrast material because of its dual blood supply and the need to complete imaging before equilibrium occurs between the intravascular and extravascular compartments. The magnitude of hepatic enhancement that is ultimately achieved is related primarily to the amount of iodinated contrast material that accumulates in the extravascular space within the target organ, independent of the speed of the CT scanner. The key determinant of the onset of the equilibrium phase is the injection duration. Given that a high injection flow rate (4–5 ml/s) is desirable for arterial phase imaging, the injection duration is maintained with use of an appropriate contrast volume. Thus, modifications of total iodine dose are best done with alterations in contrast concentration. The magnitude of arterial enhancement that is achieved is related to both the concentration and rate of contrast administration. The speed of the scanner determines its ability to record image data during the most advantageous time period, the peak of arterial enhancement. Thus, rapid imaging is particularly advantageous for optimal contrast use in CT angiography as well as in multiphasic imaging of the parenchymal organs.